Chrysarobin | CAS# 491-59-8 | ringworm, psoriasis, and eczema

MedKoo Cat#: 412851 | Name: Chrysarobin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Chrysarobin is an extract of Goa powder; a complex mixture of reduction products of chrysophanic acid, emodin, and emodin monomethyl ether; used locally in ringworm, psoriasis, and eczema. from NCIt. Chrysophanol-9-anthrone is a member of anthracenes. It derives from an anthralin.

Chemical Structure

Chrysarobin

CAS#491-59-8

Theoretical Analysis

MedKoo Cat#: 412851

Name: Chrysarobin

CAS#: 491-59-8

Chemical Formula: C15H12O3

Exact Mass: 240.0786

Molecular Weight: 240.26

Elemental Analysis: C, 74.99; H, 5.03; O, 19.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Chrysarobin; CCRIS5597; CCRIS-5597; CCRIS 5597

IUPAC/Chemical Name

3-methylanthracene-1,8,9-triol

InChi Key

JBGKVNQFVAJOGC-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H12O3/c1-8-5-10-7-9-3-2-4-11(16)13(9)15(18)14(10)12(17)6-8/h2-7,16-18H,1H3

SMILES Code

Cc(cc1O)cc2c1c(O)c(c(O)ccc3)c3c2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 240.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: BOYMOND P, JADASSOHN W. A propos de la chrysarobine [About chrysarobin]. Dermatologica. 1947;94(4):228-30. French. PMID: 18898893. 2: Kruszewski FH, DiGiovanni J. Alterations in epidermal polyamine levels and DNA synthesis following topical treatment with chrysarobin in SENCAR mice. Cancer Res. 1988 Nov 15;48(22):6390-5. PMID: 3180057. 3: Kruszewski FH, Conti CJ, DiGiovanni J. Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice. Cancer Res. 1987 Jul 15;47(14):3783-90. PMID: 3109733. 4: DiGiovanni J, Decina PC, Prichett WP, Cantor J, Aalfs KK, Coombs MM. Mechanism of mouse skin tumor promotion by chrysarobin. Cancer Res. 1985 Jun;45(6):2584-9. PMID: 3986797. 5: Battalora MS, Conti CJ, Aldaz CM, Slaga TJ, Johnston DA, DiGiovanni J. Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice. Carcinogenesis. 1996 May;17(5):955-60. doi: 10.1093/carcin/17.5.955. PMID: 8640943. 6: Battalora MS, Kruszewski FH, DiGiovanni J. Inhibition of chrysarobin skin tumor promotion in SENCAR mice by antioxidants. Carcinogenesis. 1993 Dec;14(12):2507-12. doi: 10.1093/carcin/14.12.2507. PMID: 8269619. 7: DiGiovanni J, Kruszewski FH, Chenicek KJ. Modulation of chrysarobin skin tumor promotion. Carcinogenesis. 1988 Aug;9(8):1445-50. doi: 10.1093/carcin/9.8.1445. PMID: 3135955. 8: NANASI P, KOCSIS A. Beitrag zum Wirkungsmechanismus des Chrysarobins [Pharmacology of chrysarobin]. Dermatol Wochenschr. 1951;124(41):1001-3. Undetermined Language. PMID: 14905945. 9: O'Brien TG, O'Donnell K, Kruszewski FH, DiGiovanni J. Presence of a functionally altered ornithine decarboxylase activity in chrysarobin-promoted mouse epidermal papillomas. Carcinogenesis. 1988 Nov;9(11):2081-5. doi: 10.1093/carcin/9.11.2081. PMID: 3141077. 10: Sehgal VN, Verma P, Khurana A. Anthralin/dithranol in dermatology. Int J Dermatol. 2014 Oct;53(10):e449-60. doi: 10.1111/j.1365-4632.2012.05611.x. Epub 2014 Sep 10. PMID: 25208745.